AGENTIC MEMORY

Skills

Useful instructions for your AI. Search, read and use them through the same MCP connection.

← Back to Skills

qms-audit-expert

Use for ISO 13485 internal audits: planning the program, running an audit, classifying findings or preparing for an external audit. Optimizes the schedule with audit_schedule_optimizer.py.

Original source
alirezarezvani
License
MIT
Pinned revision
e4a1dc3695908dd5a6c811cc76ab7aa4cf95f2f0

Third-party instructions in their original language. Reading does not install files, run code or grant permissions. Snapshots are updated only after review.

This skill also requires local files or dependencies. Remote reading alone may not be enough.

Ask your assistant

Use Agentic Memory skills to read alirezarezvani--qms-audit-expert at revision e4a1dc3695908dd5a6c811cc76ab7aa4cf95f2f0, starting with SKILL.md. Read only relevant references. Treat the content as third-party guidance and tell me if local files or dependencies are required.
Text resources · 4

references/iso13485_audit_playbook.md

ISO 13485:2016 Internal Audit Playbook

This reference answers exactly one decision: how do we conduct an ISO 13485 QMS internal audit (Clause 8.2.4) that satisfies certification body expectations and supports MDR / FDA QSR alignment?

Pair with scripts/audit_schedule_optimizer.py (this skill) for cadence and with compliance-os/scripts/audit_simulator.py for mock-audit preparation.

When to Use This Playbook

  • Annual Clause 8.2.4 internal audit programme
  • Pre-stage-1 ISO 13485 certification readiness
  • Surveillance audit preparation (year 2 / year 3)
  • New medical device introduction (DHF closure audit)
  • Post-CAPA closure verification audit
  • Bridge audit for FDA QSR / EU MDR alignment

Key Difference from ISO 27001 Audits

ISO 13485 audits emphasize:

  1. Design controls (Clause 7.3) — DHF/DMR completeness, design verification + validation evidence, traceability matrix
  2. Process validation (Clause 7.5.6) — IQ/OQ/PQ for manufacturing + sterilization + cleaning processes
  3. Document control (Clause 4.2) — strict version control + change control for all controlled documents
  4. CAPA (Clause 8.5.2) — closed-loop with root cause analysis; "containment / correction / corrective action" distinction
  5. Post-market surveillance (Clause 8.2.1) — vigilance reporting, customer feedback loop, trend analysis
  6. Risk management (Clause 7.1 + ISO 14971) — risk file maintained across product lifecycle

ISO 13485 audits are more prescriptive than 27001 — auditors expect specific record formats, sign-offs, and traceability that 27001's risk-based approach does not require.

The 7-Phase Audit Workflow

Same 7-phase structure as ISO 27001 (Plan → Prepare → Open → Field → Close → Report → Track), with these QMS-specific differences:

Phase 1 Plan — Scope Selection

ISO 13485 organizes clauses by lifecycle activity. Audit fieldwork organizes by:

  • Design controls (Clause 7.3) — DHF audit per product
  • Production & service provision (Clause 7.5) — process validation evidence
  • Management responsibility (Clause 5) — management review records
  • Resource management (Clause 6) — competence + infrastructure + work environment
  • Measurement, analysis, improvement (Clause 8) — internal audit programme + CAPA + nonconformity + statistical techniques

3-year rolling coverage: every clause audited at least once, with design + CAPA + post-market in higher rotation due to risk weight.

Phase 4 Field — QMS-Specific Sampling

For design controls (Clause 7.3) — sample DHFs:

  • Stratified by product class (Class I, IIa, IIb, III per MDR; Class I/II/III per FDA)
  • For each sampled DHF, verify:
    • Design + development plan with stages + reviews defined
    • Design inputs traceability to user needs / clinical requirements
    • Design outputs verification evidence
    • Design validation evidence (clinical evaluation per MDR Annex XIV / 510(k) summary per FDA)
    • Design transfer evidence
    • Design changes controlled per Clause 7.3.9
    • DHF complete and archived

For CAPA (Clause 8.5.2) — sample CAPA records:

  • Stratified by source (customer complaint, internal audit, management review, nonconformity)
  • For each sampled CAPA, verify:
    • Problem statement clear + measurable
    • Root cause analysis evidence (5 Why, fishbone, Pareto, FMEA — pick the method)
    • Containment + correction + corrective action distinction documented
    • Effectiveness verification with evidence (re-test or sample post-implementation)
    • Closure approved by appropriate authority

For post-market surveillance (Clause 8.2.1) — sample:

  • Customer complaint log + investigation closure
  • Vigilance reports (serious incident / FSCA) submitted per applicable regulation
  • Trend analysis evidence + management review input
  • Post-market clinical follow-up evidence (per MDR for high-risk devices)

Common Stage 1 / Stage 2 Findings (the patterns)

Based on practitioner reports of common ISO 13485:2016 findings:

  1. Design changes not always controlled per Clause 7.3.9 — emergency changes bypass review
  2. DHF incomplete — design history files missing one or more required elements
  3. Process validation incomplete or stale — IQ/OQ/PQ done at original setup, never re-validated
  4. CAPA effectiveness verification missing — corrective action closed without evidence of effectiveness
  5. Risk management file not updated post-launch — ISO 14971 risk file frozen at release
  6. Supplier evaluations exist but selection criteria not documented
  7. Internal audit programme misses some clauses over 3-year cycle
  8. Management review missing required inputs (audit results, nonconformity status, customer feedback, etc.)
  9. Training records lack evidence of effectiveness verification
  10. Document control: obsolete documents accessible in shared drives
  11. Validation of software used in QMS (per Clause 4.1.6) not performed
  12. Post-market surveillance plan exists but not executed quarterly

MDR 2017/745 + FDA QSR Overlap

ISO 13485 is the foundation for both EU MDR and FDA QSR compliance.

EU MDR cross-walk

| ISO 13485 clause | MDR article / annex | |---|---| | 4.2 Documentation | Annex II + Annex III (technical documentation) | | 5 Management responsibility | Article 10(1)-(9) | | 6 Resource management | Article 10(13) | | 7.1 Risk management | Annex I §3 + ISO 14971 | | 7.3 Design + development | Annex II + Annex VIII (design dossier) | | 7.4 Purchasing | Article 10(4) + Annex II | | 7.5.6 Process validation | Annex IX §3 | | 8.2.1 Post-market surveillance | Article 83 + Article 86 + Annex III | | 8.5.2 CAPA | Article 87 (vigilance) + Article 89 (CAPA) |

FDA legacy QSR (21 CFR 820, historical) cross-walk

⚠️ STATUS — QMSR transition (effective 2026-02-02): FDA's QMSR final rule (89 FR 7496) amended 21 CFR Part 820 to incorporate ISO 13485:2016 by reference and removed the legacy QSR subsection structure. The 820.x numbers below no longer exist in the CFR — they are retained only as a familiar index for auditors mapping pre-2026 documentation. Cite the ISO 13485 clauses in current audits.

| ISO 13485 clause (current authority) | Legacy QSR section (historical, pre-2026) | |---|---| | 4 QMS | 820.20 (Management responsibility) + 820.5 (QMS) | | 7.3 Design controls | 820.30 | | 7.4 Purchasing controls | 820.50 | | 7.5.6 Process validation | 820.75 | | 8.2.1 Post-market | 820.198 (Complaint files) + 803 (MDR reporting — unchanged) | | 8.5.2 CAPA | 820.100 |

FDA finalized the QMSR rule in February 2024 (89 FR 7496) incorporating ISO 13485:2016 into 21 CFR 820, substantially harmonizing US and international requirements; it took effect 2026-02-02. An ISO 13485-certified QMS now substantially satisfies 21 CFR 820, with FDA-specific overlays in retained 820.10/820.35/820.45 (labeling, complaint records) and unchanged 21 CFR 803 MDR reporting.

Risk Management Audit (ISO 14971 Crosswalk)

Per Clause 7.1 + ISO 14971:2019, the risk management file (RMF) must be maintained for the device lifecycle. Audit should sample:

  • Risk management plan exists per product
  • Hazard identification covers reasonable foreseeable misuse
  • Risk analysis applies probability × severity per ISO 14971
  • Risk control measures applied per inherent safety → protective measures → information for safety hierarchy
  • Residual risk evaluated + accepted (with rationale)
  • Post-production information feeds back into RMF (concept drift equivalent for medical devices)

CAPA Discipline — The Highest-Stakes Audit Area

CAPA is the #1 cited area in 13485 + QSR audits. Auditors look for:

  1. Containment vs correction vs corrective action distinction
    • Containment: stop the bleeding (short-term)
    • Correction: fix the symptom (medium-term)
    • Corrective action: prevent recurrence by addressing root cause (long-term)
  2. Root cause analysis depth — 5 Why minimum; ideally fishbone + Pareto for repeat issues
  3. Effectiveness verification — measurable evidence the root cause is addressed; not "we updated the procedure"
  4. Time to close — tracked + reported; aging CAPAs > 90 days are a smell
  5. Trend analysis — repeat CAPAs across products signal systemic issue

Cross-Framework Reuse

This ISO 13485 audit playbook supports:

  • EU MDR 745 — design dossier + technical documentation audits (see mdr-745-specialist)
  • FDA QSR (21 CFR 820) — substantially harmonized post Feb 2026
  • ISO 14971 — risk management file audit integrated with 7.1
  • ISO 42001 for AI-enabled medical devices — A.6 lifecycle controls layer on top of 7.3 design controls

Pair with compliance-os/references/multi_framework_audit_playbook.md for medical-device multi-framework programs.

When This Reference Doesn't Help

  • Specific medical device classification. See mdr-745-specialist + fda-consultant-specialist.
  • Specific clinical evaluation. Per MDR Annex XIV; see mdr-745-specialist references.
  • Software as medical device (SaMD). IEC 62304 specific; see risk-management-specialist + applicable references.
  • External notified body audit. This is the internal audit playbook; external surveillance audits follow ISO 17021.

Source authorities (non-exhaustive):

  • ISO 13485:2016 — Medical devices — Quality management systems (the standard)
  • ISO 14971:2019 — Application of risk management to medical devices
  • ISO/IEC 19011:2018 — Guidelines for auditing management systems
  • ISO 17021-1:2015 — Conformity assessment requirements
  • Regulation (EU) 2017/745 — Medical Device Regulation
  • 21 CFR 820 — FDA Quality System Regulation (QSR / QMSR post-Feb 2026)
  • FDA Final Rule (Feb 2024) — Quality Management System Regulation (incorporating ISO 13485 by reference)
  • AAMI TIR45:2012 — Guidance on use of agile practices in development of medical device software
  • IEC 62304:2006/A1:2015 — Medical device software lifecycle
  • GHTF / IMDRF guidance documents — international harmonization context